<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00439634</url>
  </required_header>
  <id_info>
    <org_study_id>DRI6726</org_study_id>
    <nct_id>NCT00439634</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia</brief_title>
  <acronym>CONNECT</acronym>
  <official_title>A 24-Week, Multicenter, Double-Blind, Randomized, Parallel-Group, Dose Ranging Study of the Efficacy and Safety of 3 Oral Doses of AVE1625 and Placebo on Top of Either Olanzapine, Risperidone/Paliperidone, Quetiapine or Aripiprazole in the Treatment of Cognitive Impairment in Schizophrenia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      AVE1625 is a new potent and selective cannabinoid 1 (CB1) antagonist in clinical development
      for the treatment of cognitive impairment in patients diagnosed with schizophrenia.

      The main objective of this study is to evaluate the efficacy on cognitive impairment of 3
      doses of AVE1625 using a new cognitive battery called Measurement and Treatment Research to
      Improve Cognition in Schizophrenia (MATRICS) in schizophrenic patients.

      The secondary objectives are to measure the efficacy of AVE1625 on functional capacity of the
      patients using a specific scale called University of California San Diego Performance-based
      Skills Assessment 2 (UPSA2) and to assess the safety of the compound.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Following a pre-specified interim analysis and Data Monitoring Committee recommendation due to
    insufficient level of efficacy
  </why_stopped>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the MATRICS Cognitive Battery composite standardized score</measure>
    <time_frame>at week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the UPSA2 total score</measure>
    <time_frame>at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional scales used for schizophrenia</measure>
    <time_frame>at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: physical examination, vital signs, ECGs, laboratory parameters, adverse events</measure>
    <time_frame>study period</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">873</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AVE1625 dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AVE1625 dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AVE1625 dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AVE1625</intervention_name>
    <description>oral administration</description>
    <arm_group_label>AVE1625 dose level 1</arm_group_label>
    <arm_group_label>AVE1625 dose level 2</arm_group_label>
    <arm_group_label>AVE1625 dose level 3</arm_group_label>
    <other_name>Drinabant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients with diagnosis of schizophrenia (diagnosed â‰¤ 35 years of age).

          -  Current treatment consisting exclusively of olanzapine, risperidone/paliperidone,
             quetiapine or aripiprazole monotherapy for at least 2 months.

        Exclusion Criteria:

          -  Inpatient hospitalization within past 3 months.

          -  Residence at the current address &lt; 3 months due to any instability in the disease.

          -  Presence of depressive symptoms.

          -  Past history of clinically significant violent behavior.

          -  Substance dependence or abuse.

          -  Pregnant or breast-feeding women or women not protected by effective contraceptive
             method of birth control.

        The investigator will evaluate whether there are other reasons why a patient may not
        participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2007</study_first_submitted>
  <study_first_submitted_qc>February 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2007</study_first_posted>
  <disposition_first_submitted>April 18, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>April 18, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 18, 2016</disposition_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>psychometrics</keyword>
  <keyword>schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

